A joint research group of Protocera Co., Ltd. with Associate Professor Yuji Naito and Professor Kazuhiko Uchiyama of Kyoto Prefectural University of Medicine has developed five types of peptides discovered by Protocera's new mass spectrometry method (BLOTCHIP (R) -MS method: patented). Has been shown to be useful for serum screening tests for early-stage colorectal cancer.
Colorectal cancer is a disease that can be completely cured by early detection, and screening tests for reducing mortality are important. Is inadequate.Colonoscopy is also not suitable for screening tests for medical examinations due to the heavy burden on patients and the shortage of facilities and doctors that can perform it.
Protocera Co., Ltd. (a consolidated subsidiary of Ushio Denki Co., Ltd.) has so far discovered and identified a group of peptides that specifically change in the sera of colorectal cancer patients, and a combination of five types of peptides is a combination of five types of peptides in the large intestine. He reported that it was useful for detecting cancer.This time, 5 types of peptides were measured using sera collected from healthy subjects and colorectal cancer patients, and a risk index value of 5 to 0 was calculated. It was found that the risk index in serum was significantly higher in cancer patients than in healthy subjects.
In the future, screening tests using this research method will make it possible to diagnose early-stage colorectal cancer, and it is expected that it will contribute to a significant reduction in the mortality rate from colorectal cancer.
